Source: International Congress 2017 – Novel pro- and anti-fibrotic mechanisms in pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Hallgren (Lund, Sweden). Perlecan and heparan sulphate are abundant in fibroblast foci in Idiopathic Pulmonary Fibrosis.. 1028

Member's Comments

No comment yet.

Related content which might interest you: Lung heparan and chondroitine sulfate imbalance and functional changes in pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Metabolic shift during TGF- β-induced collagen synthesis Source: International Congress 2016 – IPF pathogenesis Year: 2016 Diaphragm dysfunction in chronic obstructive pulmonary disease: a role for heparan sulphate? Source: Eur Respir J 2007; 30: 80-89 Year: 2007 FGFR4 has pro fibrotic properties in Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Translational therapeutic advances Year: 2020 Alterations in the expression of proteoglycans and glycosaminoglycans in pulmonary hypertension Source: Eur Respir J 2006; 28: Suppl. 50, 659s Year: 2006 Fine structural modifications of heparan sulfate sulfation patterns in lung are associated with functional effects in Precapillary Pulmonary Hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 Identification of profibrotic cells in the Idiopathic Pulmonary Fibrosis (IPF) lung Source: Virtual Congress 2020 – Idiopathic pulmonary fibrosis and interstitial lung disease: progression, genes and more Year: 2020 Matrix proteoglycans as effector molecules for epithelial cell function Source: Eur Respir Rev 2005; 14: 137-144 Year: 2005 Pulmonary fibroblasts are affected by notch ligands in vitro Source: International Congress 2015 – Airway remodelling: recent developments Year: 2015 Role of MUC1 in idiopathic pulmonary fibrosis Source: International Congress 2016 – ILD pathogenesis Year: 2016 Elevated protein arginine methyltransferase 1 expression contributes to the pathogenesis of pulmonary fibrosis Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Implication of FGFR4 and its ligands in Idiopathic Pulmonary Fibrosis Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018 Hypoxia-inducible factor pathway activation promotes bone-type collagen cross-linking in Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019 Effect of pirfenidone on TGF-beta-induced pro-fibrotic effects in primary human lung cells derived from patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Pirfenidone and BIBF1120 regulate properties of myofibroblasts Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Treprostinil effectively inhibits PDGF and TGF-ß1 induced extracellular matrix composition by IPF fibroblasts Source: International Congress 2015 – Therapeutic approaches in inflammatory lung disease Year: 2015 Epithelial mesenchymal transition in fibroblastic foci of different fibrosing lung diseases: Repair or remodeling? Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: pathogenesis Year: 2013 Dasatinib suppresses TGFbeta-induced epithelial mesenchymal transition and inhibits pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 BIBF1120 inhibits fibroblasts proliferation and production of the extracellular matrix protein fibulin-1 Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease Year: 2015 Parenchymal cell populations involved in the development of fibrosis Source: International Congress 2014 – ILDs 4 Year: 2014